KYNB:NASDAQ
Kyntra Bio Inc
$ 5.12
arrow_downward
-1.63%(-0.085) 1D
10-р сарын 22, 16:00:00 (GMT-4) · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for KYNB...
Open
$ 5.17
High
$ 5.34
Low
$ 5.00
Mkt. cap
20.75 сая
Avg. vol.
26.76 мян
Volume
9.54 мян
P/E ratio
0.11
52-wk high
$ 9.70
52-wk low
$ 4.85
EPS
$ 45.30
Beta
1.05
Shares outstanding
4.05 сая
No. of employees
34
Open
$ 5.17
High
$ 5.34
Low
$ 5.00
Mkt. cap
20.75 сая
Avg. vol.
26.76 мян
Volume
9.54 мян
P/E ratio
0.11
52-wk high
$ 9.70
52-wk low
$ 4.85
EPS
$ 45.30
Beta
1.05
Shares outstanding
4.05 сая
No. of employees
34
News stories
From web sources and news partners
Yahoo Finance
·
34 минутын өмнө
Nasdaq: 3 Key Takeaways for Long-Term Investors
BeInCrypto
·
17 минутын өмнө
Is the S&P 500 No Longer the Economy? DataTrek's Nick Colas Weighs In
Stocktwits
·
32 минутын өмнө
Nasdaq Futures Rise After Chip Selloff While S&P 500, Dow Track Mixed Open: SLV, GLD, SOXL, BE In Focus
CBS News
·
7 цагийн өмнө
Nasdaq dives more than 750 points as investors worry massive AI spending won't pay off
Profile
Kyntra Bio, Inc. is a biopharmaceutical company headquartered in San Francisco, California. Once regarded as a promising developer of innovative therapies for anemia and fibrotic diseases, with a market capitalization of roughly $4 billion in 2018–19, the company's value collapsed following late-stage trial failures, regulatory setbacks, and a data manipulation scandal. By 2026, Kyntra was mainly reduced to a single early-stage oncology drug candidate.
On January 8, 2026, FibroGen changed its name to Kyntra Bio and ticker symbol to KYNB. Wikipedia
About Kyntra Bio Inc
CEO-
Employees34
Founded1993 оны 1-р сарын 1
HeadquartersСан-Франциско, Калифорни, Америкийн Нэгдсэн Улс
Sector-
Websitekyntrabio.com